Can Grape Seed Extract Kill Cancer Cells?

It sounds strange but the short answer is yes. Researchers from the University of Kentucky found that applying extract from grape seeds to laboratory leukemia cells forced them to commit suicide. In a 24 hour period, 76% of all lab cancer cells had died after being exposed to the grape seed extract.



How does this work? The researchers believe that the extract activates the protein JNK which regulates apoptosis, or cell death. An important fact is to note is that the extract did not affect normal cells. They do not know why this occurred.



This extract has been shown to have an activity in cancer cell lines such as skin cancer, breast cancer and lung cancer. Yet this is the first time this has been shown for Hematological cancers which include leukemia, lymphoma and myeloma.



Even though the work here is preliminary, the importance lies in the fact that natural occurring agents can be used in the treatment/prevention of cancers.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap